113: 499506 Sima AAF, Brismar T
Some patients benefit from a lower maintenance dose of semaglutide rather than complete discontinuation, which allows ongoing appetite management at lower cost while preventing the weight-loss plateau effect that can occur with continuous high-dose therapy
These compounds increase the activity of certain neurotransmitters in the brain, primarily dopamine and norepinephrine
A primary cause is the medications effect on gastric motility, leading to slower digestion and a sensation of fullness that may reduce overall caloric intake
Lancet 394:131138 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Thats one of the biggest concerns I have as a pharmacist